Upadacitinib

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more.

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.

In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.

The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.